Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Conditions
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Trial Timeline
Sep 11, 2014 → Feb 27, 2017
NCT ID
NCT02214121About Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b
Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b is a phase 2 stage product being developed by AstraZeneca for Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02214121. Target conditions include Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02214121 | Phase 2 | Completed |
Competing Products
2 competing products in Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Acetylsalicylic acid (Fast release Aspirin, BAY1019036) + Acetylsalicylic Acid (Aspirin, BAYE4465) + Placebo | Bayer | Phase 3 | 74 |
| Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + Placebo | Bayer | Phase 3 | 74 |